A novel strategy to suppress triple negative breast cancer growth

In 2022, a team of researchers at Baylor College of Medicine discovered that a little-known enzyme called MAPK4 is involved in the growth of triple negative breast cancer (TNBC) and its resistance to certain therapies. Looking into the details of this novel role of MAPK4, the researchers have now identified a strategy that can potentially control MAPK4-promoted growth in TNBC and other cancers. The study, published in PLOS Biology, opens new options for treating this devastating disease.